Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.

被引：95
|
作者：
Llovet, Josep M.
Kudo, Masatoshi
Cheng, Ann-Lii
Finn, Richard S.
Galle, Peter R.
Kaneko, Shuichi
Meyer, Tim
Qin, Shukui
Dutcus, Corina E.
Chen, Erluo
Dubrovsky, Leonid
Zhu, Andrew X.
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Kindai Univ, Sch Med, Osakasayama, Japan
[3] Natl Taiwan Univ Hosp, Ctr Canc, Taipei, Taiwan
[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[5] Johannes Gutenberg Univ Mainz, Med Ctr, Mainz, Germany
[6] Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan
[7] UCL, Inst Canc, London, England
[8] Peoples Liberat Army, Hosp 81, Nanjing, Jiangsu, Peoples R China
[9] Eisai Inc, Woodcliff Lake, NJ USA
[10] Merck & Co Inc, Kenilworth, NJ USA
[11] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS4152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4152
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN plus PEMBRO) or sunitinib (SUN) in the CLEAR study.
    Voss, Martin H.
    Powles, Thomas
    McGregor, Bradley Alexander
    Porta, Camillo
    Gruenwald, Viktor
    Merchan, Jaime R.
    Rolland, Frederic
    Maroto-Rey, Pablo
    Goh, Jeffrey C.
    Xing, Dongyuan
    Perini, Rodolfo F.
    McKenzie, Jodi
    Mody, Kalgi
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)
    Cheng, A. -L.
    Finn, R. S.
    Qin, S.
    Han, K. -H.
    Ikeda, K.
    Piscaglia, F.
    Baron, A.
    Park, J. -W.
    Han, G.
    Jassem, J.
    Blanc, J. F.
    Vogel, A.
    Komov, D.
    Evans, T. J.
    Lopez, C.
    Dutcus, C.
    Ren, M.
    Kraljevic, S.
    Tamai, T.
    Kudo, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 211 - 211
  • [23] First-line lenvatinib (Len) plus pembrolizumab (Pembro) plus chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in
    Shitara, K.
    Ben-Aharon, I.
    Rojas, C.
    Eyzaguirre, D. A. Acosta
    Hubert, A.
    Moya, H. Araya
    Cohen, D.
    Bai, L-Y.
    Ghiringhelli, F.
    Wyrwicz, L.
    Janjigian, Y. Y.
    Tabernero, J.
    Van Cutsem, E.
    Qin, S.
    Xu, J.
    Wang, A.
    Miller, M. G.
    Shih, C-S.
    Bhagia, P.
    Weber, P. E. Yanez
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1108 - S1108
  • [24] A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Zhu, A. X.
    Finn, R. S.
    Mulcahy, M. F.
    Gurtler, J. S.
    Sun, W.
    Schwartz, J. D.
    Rojas, P.
    Dontabhaktuni, A.
    Youssoufian, H.
    Stuart, K. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti PD-1/PD-L1 agents: Phase 2 LEAP 004 study.
    Fernandez, Ana Maria Arance
    Ascierto, Paolo Antonio
    Carlino, Matteo S.
    Daud, Adil
    Eggermont, Alexander M.
    Hauschild, Axel
    Kluger, Harriet M.
    Taylor, Matthew H.
    Smith, Alan
    Chen, Ke
    Krepler, Clemens
    Diede, Scott J.
    O'Day, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
    Ikeda, Masafumi
    Sung, Max W.
    Kudo, Masatoshi
    Kobayashi, Masahiro
    Baron, Ari D.
    Finn, Richard S.
    Kaneko, Shuichi
    Zhu, Andrew X.
    Kubota, Tomoki
    Kralijevic, Silvija
    Ikezawa, Hiroki
    Siegel, Abby B.
    Kumada, Hiromitsu
    Okusaka, Takuji
    CANCER RESEARCH, 2019, 79 (13)
  • [27] A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
    Llovet, J.
    Shepard, K. V.
    Finn, R. S.
    Ikeda, M.
    Sung, M.
    Baron, A. D.
    Kudo, M.
    Okusaka, T.
    Kobayashi, M.
    Kumada, H.
    Kaneko, S.
    Pracht, M.
    Mamontov, K.
    Meyer, T.
    Mody, K.
    Kubota, T.
    Saito, K.
    Siegel, A. B.
    Dubrovsky, L.
    Zhu, A. X.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Phase III Trial of Lenvatinib (LEN) vs Sorafenib (SOR) in First-Line Treatment of Patients (PTS) with Unresectable Hepatocellular Carcinoma (uHCC)
    Cheng, Ann-Lii
    Finn, Richard S.
    Qin, Shukui
    Han, Kwan-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    Lopez, Carlos
    Dutcus, Corina
    MinRen
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Bower, John
    Kudo, Masatoshi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 116 - 116
  • [29] Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    Cheng, Ann-Lii
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari David
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean -Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    -Lopez, Carlos Lopez
    Dutcus, Corina E.
    Ren, Min
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, C. G.
    Eto, M.
    Motzer, R. J.
    De Giorgi, U. F. F.
    Buchler, T.
    Basappa, N. S.
    Mendez Vidal, M. J.
    Tjulandin, S.
    Park, S. H.
    Melichar, B.
    Hutson, T. E.
    Alemany, C.
    McGregor, B.
    He, C. S.
    Perini, R.
    Mody, K.
    McKenzie, J.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1205 - +
12345